BERLIN — BioNTech expects results by September from trials testing the COVID-19 vaccine that it and Pfizer have developed in babies as young as six months old, German magazine Spiegel cited the company’s CEO as saying. “In July, the first results could be available for the five to 12 year olds, in September for the younger children,” BioNTech Chief Executive Ugur Sahin told Spiegel. A spokeswoman for BioNTech confirmed the expected timeline for the trial results in younger children. BioNTech and Pfizer asked U.S. regulators this month to approve emergency use of their vaccine for adolescents aged 12 to 15. A trial published at the end of March found the companies’ COVID-19 vaccine was safe, effective and produces robust antibody responses in adolescents.

Source: Philippine Daily Inquirer April 29, 2021 09:33 UTC